Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. filed a Form 6-K to notify investors that it will release its fiscal year and fourth quarter 2025 financial results on March 11, 2026, before U.S. market open. Management will host an investment community conference call that day at 8:30am Eastern Time.
The notice also highlights Kamada’s focus on specialty plasma-derived therapies for rare and serious conditions, its three plasma collection centers in Texas, and its growth strategy based on organic expansion, in-licensing, plasma collection, and potential mergers and acquisitions.
Kamada Ltd. is providing a positive outlook for the next two years. For 2026, the company guides to revenues of $200–$205 million and $50–$53 million of adjusted EBITDA, which it says reflects double-digit profitable growth based solely on continued organic expansion of its proprietary plasma therapies and distribution businesses. The midpoint of this range represents about a 13% revenue increase and 23% adjusted EBITDA increase over its 2025 guidance midpoints.
Kamada also affirms its 2025 guidance of $178–$182 million in revenues and $40–$44 million of adjusted EBITDA, and it expects 2025 year-end cash of approximately $75 million. Management cites growth across its global portfolio, including products such as KAMRAB, GLASSIA, HEPAGAM and VARIZIG, launches of biosimilars in Israel, expansion of its distribution business into the MENA region, and increasing plasma collection in its three U.S. centers, even as a reduced GLASSIA royalty rate from Takeda weighs on 2026.
Kamada Ltd. submitted a Form 6-K as a foreign private issuer, highlighting an attached exhibit about a commercial development. The exhibit states that Kamada announced a $10–$14 million extension of a Canadian supply tender. This indicates that an existing Canadian supply arrangement has been extended with an estimated value in that range, and the company is formally updating investors by incorporating this report into several existing Form S-8 registration statements.
Kamada Ltd. furnished a Form 6-K that includes a press release reporting strong third-quarter and nine‑month 2025 results, highlighting over 30% year‑over‑year profitability growth. The filing also provides a November 2025 company presentation and unaudited consolidated financial statements as of September 30, 2025. This 6‑K is incorporated by reference into Kamada’s Form S‑8 registration statements.
Kamada Ltd. furnished a Form 6-K and attached an exhibit announcing a clinical milestone for CYTOGAM. The filing states it is incorporated by reference into the company’s Form S-8 registration statements.
Exhibit 99.1 is titled “Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation.” This indicates the study is led by independent investigators and marks the start of patient enrollment focused on CMV prevention in kidney transplant recipients. The report was signed by Nir Livneh, Vice President General Counsel and Corporate Secretary.
Kamada Ltd. announced it will hold its Annual General Meeting of Shareholders on December 10, 2025 at 4:00 p.m. Israel time at the company’s offices, 2 Holzman Street, Weizmann Science Park, Rehovot, Israel.
The report states that the Notice and Proxy Statement and the proxy card are attached as Exhibits 99.1 and 99.2 and incorporated by reference. The Form 6-K is also incorporated by reference into Kamada’s Form S-8 registration statements (File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, 333-265866).
Kamada Ltd. submitted a report as a foreign private issuer stating that it files its annual reports on Form 20-F. The report is being incorporated by reference into several existing Form S-8 registration statements. It also attaches an exhibit announcing Kamada’s participation in upcoming September investor conferences.
Kamada Ltd (KMDA) reported stronger operating results in a Form 6-K filing that includes a company presentation and unaudited consolidated financial statements as of June 30, 2025. The company disclosed 11% year-over-year top-line growth for the first six months and a 35% increase in profitability over the same period. Management also raised full-year profitability guidance. The filing attaches the presentation and the Inline XBRL financial documents for more detail.
Kamada Ltd. reports that the U.S. Food and Drug Administration has approved its plasma collection center in Houston, Texas. This information is provided through a Form 6-K submission that incorporates the report by reference into several existing Form S-8 registration statements. The FDA approval of the Houston plasma collection center represents a regulatory milestone for Kamada’s plasma-related activities in the United States.